Glomerular matrix: Synthesis, turnover and role in mesangial expansion  by Couchman, John R. et al.
Kidney International, Vol. 45 (1994), pp. 328—335
Glomerular matrix: Synthesis, turnover and role in mesangial
expansion
JOHN R. COUCHMAN, LESLEY A. BEAVAN, and KEVIN J. MCCARTHY
Department of Cell Biology, University of Alabama at Birmingham, Birmingham, Alabama, USA
Glomerular matrix: Synthesis, turnover and role in mesangial expan.
sion. The extracellular matrix has an integral role in development,
homeostasis and pathology of the glomerulus. Three spatially distinct
matrices are present in the glomerulus: the mesangium, and basement
membranes of the capillary loops and Bowman's capsule. Each is
dominated by basement membrane components, but is distinct in
organization and composition. Many matrix components influence cell
behavior directly, through specific interactions with receptors, or
indirectly through growth factor sequestration. Growth factors may be
of great importance in development and disease progression in the
glomerulus, and may be central to mesangial expansion. In addition,
changes in matrix composition accompany and contribute to the patho-
logical condition, such as the accumulation of matrix in diabetes
mellitus.
It is now a central tenet of the field that extracellular matrix
molecules can, through interaction with specific receptors,
influence many aspects of cellular behavior including adhesion
and growth, migration, differentiation and repair. Studies on the
development, function and pathology of the kidney glomerulus
have underscored these attributes of extracellular matrix mol-
ecules, and have been instrumental in furthering our under-
standing of their mechanisms of action. In addition, studies on
the kidney glomerulus have indicated that extracellular matri-
ces can be highly tissue specific and may change both qualita-
tively and quantitatively through development and the onset of
disease. The kidney glomerulus has three distinct extracellular
matrices, though they all have basement membrane constitu-
ents as their major matrix type. The delimiting Bowman's
capsule has a matrix consisting of a double basement membrane
structure outside which lies pericapsular interstitial connective
tissue. The mesangium also contains mostly basement mem-
brane matrix though this is not organized in a distinct laminar
structure common to many other tissues. The third matrix is
that of the capillary loop, one of the most intensely studied of all
basement membranes. Indeed, the glomerular basement mem-
brane has been a paradigm for basement membrane research.
However, as is shown in Table 1, this basement membrane has
many unique properties, notably a distinct spectrum of type IV
collagen, and laminin isoforms. Its uniqueness is in keeping
with its role as a major filtration surface, a role not shared with
many other basement membranes. Morphologically, this base-
ment membrane is also somewhat distinct, having a central
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lamina densa bounded on two sides by the lamina rara interna
and externa. Its origin is also unusual, resulting from the fusion
of two separate basement membrane matrices of endothelial
and epithelial origin [1]. The development of glomerular base-
ment membrane is described in an accompanying article.
Despite the contiguous nature of mesangial matrix with the
glomerular basement membrane, it is clear that compartmen-
talization is rigorously controlled. The S-chain of laminin, for
example, while present in the glomerular capillary basement
membrane, is not present in the mesangium, whereas basement
membrane chondroitin sulfate proteoglycan, while abundant in
the mesangial matrix and virtually all other basement mem-
branes, is uniquely absent from the mature glomerular base-
ment membrane [2, 3].
All basement membranes contain collagen, glycoproteins and
proteoglycans, though with distinct tissue specific organization.
Type IV collagen appears to be ubiquitous in basement mem-
branes and may provide the structural basis of this specialized
matrix. The most abundant isoforms are a! and a2 chains and
these are present in all three glomerular matrices, though they
are largely replaced by other isoforms in glomerular basement
membrane [2, 4, 5]. The structure of type IV collagen is well
understood and is reviewed elsewhere [6], although the manner
in which the molecule forms polymers and networks is still not
resolved. The most abundant glycoprotein family is the lami-
nins, of which there are now many chains known. In addition to
the prototypical A, B 1, and B2 chains as isolated from the
murine transplantable EHS tumor [7], there are now several
other B-like chains and A-like chains known to exist. In the
kidney, the S-chain is abundant in the glomerular capillary loop
[2]. Laminin forms heterotrimers giving rise to asymmetric
cross shaped molecules and is a molecule capable of many
interactions with distinct cell surface receptors, notably of the
integrin family [81. Several sites capable of interacting with
receptors are now recognized, and presumably the substitution
of alternate laminin chains endows specificity of interaction
with receptors, and thereby engenders specificity of response in
the overlying cells. The multiple interactions of laminin with its
receptors have been recently reviewed [8]. A ubiquitous lami-
nm-associated glycoprotein is entactin (also known as nidogen),
a glycoprotein now thought to provide linkage between laminin
and type IV collagen in basement membranes [9]. However, it
has also been shown that laminin can self assemble into
matrices in the absence of type IV collagen under certain
circumstances [10]. Entactin may also interact directly with
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Table 1. Glomerular extracellular matrix
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Entactin + + +
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aS
+
—
-
—
(+)
+
+
+
+
—
—
—
BM-HSPG eg + + +
Perlecan (small)
BM-CSPG + — +
Fibronectin + (+) +
TypeV + + —
collagen
Decorin (+) — —
cells, although the nature of these interactions and their conse-
quences are currently unknown.
Fibronectin and transmembrane signaling
The intensively studied glycoprotein fibronectin is also
present in many basement membranes and is especially rich in
the mesangium and Bowman's capsule matrices. Its presence in
the glomerular basement membrane is somewhat controversial,
but it seems to be present in small amounts, possibly of plasma
origin [11]. However, it seems almost certain that mesangial
fibronectin is of endogenous origin, and mesangial cells in
culture synthesize extensive fibronectin-rich extracellular ma-
trices. The basic unit of fibronectin as found in the plasma is a
dimer consisting of closely similar but not identical chains.
Although there is only one gene, fibronectin can exist in
multiple forms as a result of mRNA splicing. Some of these
variations take place in the so called V-region and the two
chains of plasma fibronectin differ at this site. Fibronectin of
cellular origin may also contain extra type III repeats known as
EIIIA and EIIIB [reviewed in 12]. The control of mRNA
splicing of fibronectin is rigorous, emphasized by studies on
development and disease where distinct isoforms of fibronectin
may be inserted into the extracellular matrix. A clear example
of this is glomerulonephritis, where EIIIA+ fibronectin may be
deposited in the expanding mesangial matrix, an isoform not
seen in any significant amount in the normal kidney [13]. As
well as interacting with proteoglycans and collagens of extra-
cellular matrices, several domains of fibronectin can interact
with cell surface receptors [12]. These interactions have been
the subject of intense study, and it is now clear that fibronectin
can exert its effects on cellular behavior through transmem-
brane signaling events. Thus interaction of the well known
RGD-containing type III repeat with a51 integrin can lead to
tyrosine phosphorylation of two cytoplasmic proteins, paxillin
and ppl25' The latter is itself a tyrosine kinase although its
substrate is currently not known. In addition, evidence from
our laboratory indicates that interactions of the heparin-binding
domains of fibronectin with cell surface proteoglycans may
trigger a second transmembrane signaling event where protein
kinase C becomes activated. The consequences of these phos-
phorylation events may be cytoskeletal rearrangements, and in
tissue culture, one observes the formation of specialized adhe-
sion sites known as focal adhesions or focal contacts [15].
These are commonly found in anchorage-dependent cells plated
on extracellular matrix glycoproteins such as fibronectin, lami-
nm or type 1 collagen. Focal adhesions are localized areas of
tight cell-matrix interaction and are, in addition, termini of
microfilament bundles containing actin and associated proteins.
These structures are formed by many cell types in culture,
including vascular endothelial, mesangial and fibroblastic cells.
It is believed they may be involved in wound contraction
processes in vivo. Focal adhesions are highly enriched in a
select group of cytoplasmic and transmembrane proteins and
are often compromised in the transformed state and may be
reduced or missing in cells undergoing locomotion [15, 16]. The
control of cellular responses to fibronectin is not understood,
though it is likely that phosphorylation events are critical in
setting up the cytoskeleton either for a role in anchorage or a
more fluid organization compatible with migration. Fibronectin
may also influence basement membrane matrix deposition. It
has been recently shown that murine endodermal cells respond
t' fibronectin substrates by the increased deposition of laminin,
t3pe IV collagyn and heparan sulfate proteoglycan. Uncoated
oi type I collagen substrates do not share this property [17].
M hue the precise mechanism remains unknown, there are
pi obably some transmembrane signaling events which affect
matrix export. Secretion of matrix-degrading proteases by
fibroblasts has also been shown to be regulated by occupation
of fibronectin receptors [18].
Proteoglycans
All basement membranes appear to contain one or more
proteoglycans, of which those bearing heparan sulfate chains
predominate. Kidney basement membranes are no exception to
this and have been among the most intensely studied of all
tissue basement membrane proteoglycans (Fig. 1). While a
great range of proteoglycan core protein sizes have been
reported both from kidney and elsewhere, it is still currently
unclear just how many distinct core proteins there are in terms
of gene products. The best characterized proteoglycan to date
has now been called perlecan, a large proteoglycan first isolated
from the murine EHS tumor matrix [reviewed in 19]. The core
protein of this proteoglycan is 396 kD in the mouse, and has
been entirely sequenced [20]. It consists of five domains and is
one of the most complex of extracellular matrix molecules. At
the N-terminus there is a small domain of approximately 117
amino acids which bears virtually no homology to any previ-
ously described extracellular matrix component. Close to the
N-terminus there are three SOD repeats which may be substi-
tuted with heparan sulfate chains at the serine residues. Domain
II comprises approximately 210 amino acids with homology to
the low density lipoprotein receptor. Currently its function is
unknown and whether this molecule can bind lipoproteins is
unresolved. Domain III is very large, 1172 amino acids, and
bears homology to the short arms of laminin A and B chains. It
is therefore quite likely that this region of the molecule interacts
with cell surfaces and/or basement membrane components.
Interposed between domains II and III is a single immunoglob-
ulin (Ig)-like motif. Domain IV consists of multiple Ig repeats,
each of approximately 100 amino acids. They most closely
r•S
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Hg. 1. Indirect immunofluorescence micrographs of mouse kidney
stained with monoclonal antibodies CuLl (A) and BuLl (B) against
perlecan. While tubular and Bowman's capsule basement membranes
and mesangial matrix are stained similarly, the capillary ioop basement
membrane is well stained by B1ILI but not CuLl (arrows). Epitope
availability or abundance may be responsible for this variability in
staining pattern. Scale bars = 30 sm.
resemble those found in the cell adhesion molecule N-CAM. In
murine perlecan there are 14 Ig repeats but two reports of the
human sequence of perlecan demonstrate 21. It therefore ap-
pears quite likely that alternate splicing can take place in this
domain of perlecan. N-CAM undergoes homotypic interactions
and it is possible that this region of perlecan may also be
involved in dimerization. It may also be involved in cell
adhesion. Domain V at the C-terminal domain of perlecan
consists of approximately 700 amino acids which again have
homology with laminin A chain and an A-chain variant
(merosin) at their C-terminal globular domains. There are
differences, however, most notably that there are only three
loops in perlecan, compared with five in laminin A-chain and
merosin.
Perlecan is highly complex, not only with respect to its core
protein structure but with respect to posttranslational modifi-
cations. While this molecule was described as heparan sulfate
proteoglycan from the EHS tumor and from other cell culture
systems, the molecule can also be a hybrid proteoglycan
bearing both heparan and dermatan sulfate chains. Such a
molecule has been identified in human placenta [21] but not so
far in kidney. One report shows that perlecan can in fact be
substituted only with chondroitin/dermatan sulfate chains [22].
Where substitution with galactosaminoglycans takes place is
not known, but since there are 42 ser-gly pairs in the murine
molecule and 52 or 53 in the human, it seems likely that there is
considerable potential for glycosylation. Another complication
is that perlecan core protein may become cleaved. This has
been reported for the EHS tumor [19] and has been shown to
take place in the glomerulus [23]. However, this does not fully
explain the wide range of core protein sizes reported from
kidney studies (18 kD to 400 kD). It seems quite possible that
there are distinct species of heparan sulfate proteoglycan in the
kidney [reviewed in 16], and evidence has recently been pre-
sented of a novel basement membrane heparan sulfate proteo-
glycan with a core protein of approximately 40 kD [24]. Detailed
immunoelectron microscopy studies have also recently pointed
to the existence of more than one proteoglycan in glomerular
basement membrane, based on distinct localizations [25]. How-
ever, since the core protein of the perlecan is extremely large,
its precise organization within this basement membrane can be
hard to judge since epitopes may reside throughout the entire
width of the basement membrane. Immunoelectron studies with
domain-specific antibodies, and monoclonal antibodies may be
helpful in this regard.
In addition to heparan sulfate proteoglycans, there is at least
one chondroitin sulfate proteoglycan which is widely present in
adult tissue basement membranes (BM-CSPG). The proteogly-
can appears to be quite distinct from heparan sulfate proteogly-
cans, and our monoclonal antibodies against the core protein of
this molecule react with all adult rat basement membranes, with
the sole exception of the glomerular basement membrane [3].
This finding has been confirmed both at light and electron
microscope levels. BM-CSPG distribution therefore empha-
sizes the compartmentalization of extraceilular matrix within
the glomerulus, since the mesangium and Bowman's capsule
basement membranes stain strongly with antibodies to BM-
CSPG. The proteoglycan was first identified in rat Reichert's
membranes and has a core protein of approximately 150 kD,
bearing numerous short chondroitin sulfate chains [26]. Its
function is currently unknown, but its distribution through skin
and kidney development appears to be strongly regulated. In
the developing nephron, BM-CSPG is absent from the earliest
formed capillary loop basement membranes. Immunoreactivity
subsequently increases as the nephron matures, but is then
gradually lost during the first eight weeks of postnatal life and is
never normally regained [27].
The function of basement membrane heparan sulfate proteo-
glycans is becoming more clear and the glomerular basement
membrane provides an excellent example. Experiments have
shown that destruction of heparan sulfate chains with bacterial
enzymes can compromise the selective filtration barrier prop-
erties of glomerular capillary loops. This effect was largely
ascribed to the destruction of the heparan sulfate glycosamino-
glycans within the glomerular basement membrane [28]. Chon-
droitinase ABC treatment had no effect. However, while this
may provide strong evidence for the role of heparan sulfate
proteoglycans in the glomerular basement membrane this
clearly cannot be extrapolated to other tissues where the same
molecules may be present but a filtration function is not
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apparent. Thus, perlecan is widespread and found in all base-
ment membrane described to date. It may therefore be that
specific properties are endowed by tissue specific glycosylation
patterns in this and related molecules. It has recently been
described that perlecan may promote cell adhesion through
members of the and J33 classes of integrin receptors [29].
Another clearly important function of basement membrane
proteoglycans may be to bind and sequester growth factors, and
protect them from proteolysis. It has been demonstrated that
basic fibroblast growth factor (bFGF) will bind strongly to
heparan sulfate and can be identified in some basement mem-
branes [30]. Since basic FGF may be important in some
proliferative kidney diseases [311 this may be a very important
facet of the biology of basement membrane proteoglycans, as
well as cell surface proteoglycans such as the syndecans. There
are many heparin-binding growth factors which may also po-
tentially interact with heparan sulfate chains, such as TGF-/3,
and hepatocyte growth factor/scatter factor (HGF/SF). It is in
fact becoming increasingly difficult to distinguish between base-
ment membrane components and growth factors since they may
co-distribute, and in many cases interactions of matrix mole-
cules and growth factors with cell surfaces may lead to the same
type of transmembrane signaling and second messenger re-
sponses.
Decorin and mesangial expansion
Expansion of the mesangium plays a significant role in most
progressive glomerular diseases leading to morbidity and death
and is thought to be due primarily to increased matrix deposi-
tion [32]. In addition to basement membrane proteoglycans, the
interstitial proteoglycan decorin may be involved in mesangial
expansion. Decorin is a member of the leucine-rich small
chondroitin/dermatan sulfate proteoglycans, characterized by a
core protein of 36 kD, bearing only one glycosaminoglycan
chain [33]. Decorin interacts with fibronectin and collagens I, II
and VI and influences fibrillogenesis, cell adhesion and prolif-
eration [33—35].
Using sequence specific antibodies and in situ hybridization,
Bianco et al [36] demonstrated that decorin is associated with
the majority of type land II collagen-rich tissue matrices, which
further supports its role in regulating collagen fiber assembly
and growth. In kidney, it was localized to interstitial connective
tissue with focal concentrations around tubular structures and
the adventitia of arteries. Negligible amounts were associated
with mesangia of developing human kidney, but adult human
mesangial cells secrete two small dermatan sulfate proteogly-
cans in vitro, identified as decorin and biglycan [37].
Mesangial cell behavior is influenced by the presence of the
surrounding matrix and cytokines. TGF-/3 may contribute to the
increase in extracellular matrix components in mesangial ex-
pansion by stimulating their synthesis or decreasing extracellu-
lar protease activity. This cytokine is known to up-regulate
synthesis of proteoglycans such as decorin. It has a differential
effect on matrix production by rat glomerular epithelial and
mesangial cells. Both cell types produced increased amounts of
proteoglycan but only epithelial cells also synthesized an in-
crease in non-proteoglycan components [38]. This overall en-
hancement of matrix production probably contributes to the
expanded matrices seen in disease states which are associated
with increased TGF-f3 production.
TGF-f3 may mediate a pathological increase of extracellular
matrix in progressive glomerulosclerosis. It is not known pre-
cisely which cell types are responsible for its expression in the
human glomerulus or what stimulates its secretion. TGF-13
mRNA and protein are expressed by isolated glomeruli [39] and
Kaname et al [40] have recently shown that TGF-13 is expressed
by rat mesangial cells in vitro where it functions as an autocrine
factor and apparently regulates growth and differentiation. In
animal models of glomerular disease, injured glomeruli in
culture produce more extracellular matrix compared with nor-
mal glomeruli, and this particularly applies to decorin. Anti-
body inhibition experiments indicated this was caused by
increased synthesis of TGF-f3 and confirmed by elevated TGF-f3
mRNA levels in glomeruli [39]. In rats with anti-Thy 1.1
nephritis, administration of anti-TGF-13 at the time of induction
suppressed production of extracellular matrix [41].
At the same time Yamaguchi, Mann and Ruoslahti [42]
demonstrated that decorin expression in CHO cells neutralized
the stimulatory effect of TGF-13 on proliferation. As TGF-/3
induces synthesis of decorin in several cell types [39], they
suggested that decorin is part of a negative feedback system
regulating cell growth. A subsequent study showed that admin-
istration of decorin in vivo inhibits the increased production of
extracellular matrix in anti-Thy 1.1 induced experimental gb-
merulonephritis in rats [13]. Hence, decorin may be involved in
controlling increased matrix deposition which appears to be
indirectly caused by the effect of TGF-J3 on its synthesis and
that of the other matrix proteins.
Mesangial expansion in diabetes mellitus
The renal histopathology and pathophysiology that occur in a
proportion of individuals afflicted with long-term insulin-depen-
dent diabetes mellitus (IDDM) has been well described. In
diabetic humans, the progression from normal renal function to
end-stage renal disease, indicated by such parameters as a
decline in glomerular filtration rate and an increase in urinary
albumin excretion, is gradual, usually occurring over the course
of 15 to 25 years. In animal models of IDDM (such as the
streptozocin rat model) these changes occur over the course of
several months. However, in both human disease and animal
models, changes in renal function are mirrored, in part, by
histoarchitectural changes that occur within the gbomerulus.
These include glomerular hypertrophy, gbomerular basement
membrane (GBM) thickening, mesangial expansion, and even-
tually, glomerulosclerosis. The reconciliation of these morpho-
logical alterations with functional changes has been the focus of
much research.
The early biochemical studies of Beisswenger and Spiro [43]
suggested that changes in the subunit composition of the
basement membrane material comprising the infrastructure of
the gbomerulus was, in part, responsible for the defective
gbomerular filtration observed in diabetics. The classic work of
Kanwar, Linker and Farquhar subsequently showed that a
heparan sulfate proteoglycan associated with the glomerular
basement membrane played an integral role in glomerular
filtration [28]. Since that time, numerous biochemical and
immunohistochemical studies have described changes occur-
ring in basement membrane heparan sulfate proteoglycan (BM-
HSPG/perlecan) promoted by the diabetic condition, including
such diverse effects as: a net decrease in the amount of
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BM-HSPG synthesized in the GBM; a net decrease in anionic
charge density of GBM BM-HSPG; and overt loss of BM-
HSPG from the glomerular basement membrane [reviewed in
161. At present, the exact nature of this "lesion" is still an area
of debate, but studies strongly indicate that changes in the
molecular integrity, biosynthetic dynamics of members of the
BM-HSPG family and/or pattern of distribution could directly
contribute to alterations in glomerular filtration function ob-
served in diabetic nephropathy.
Concurrent morphology studies employed stereologic tech-
niques to map the progressive histoarchitectural changes that
occur in diabetic nephropathy. Osterby [44] quantified the
degree of glomerular hypertrophy, GBM thickening, and in-
crease in mesangial matrix, as well as the time course of these
changes that occur in diabetic nephropathy. Subsequent struc-
ture/function studies demonstrated that the GBM thickening
that occurs at early stages, is at best weakly correlative with
albuminuria. Mesangial expansion, a measurement of the rela-
tive increase in glomerular mesangial volume fraction that
occurs in diabetic nephropathy, was one parameter that was
shown to have a strong correlation to known indicators of
altered renal function such as an increase in urinary albumin
excretion associated with the latter stages of the disease. It is
thought that these alterations in renal function could be medi-
ated in part by the encroachment of the mesangial matrix on the
peripheral capillary surface, eventually causing a net decrease
in surface area available for filtration [451.
A focus of ongoing work is the structure and function of
BM-CSPG in normal tissues, organ morphogenesis, and disease
[3, 16, 26, 27, 46]. The most striking example of the differential
distribution of BM-CSPG and heparan sulfate proteoglycan
populations occurs in the normal adult glomerulus. Using
immunohistochemical methods at the light microscope [3, 26]
and ultrastructural levels, we have shown BM-CSPO to be
restricted within the normal glomerulus to the mesangial matrix
(Fig. 2A), whereas BM-HSPG is found in both the glomerular
basement membrane and the mesangial matrix. In rodent renal
nephrogenesis this segregation of proteoglycan populations
appears to occur in the latter stages of glomerular development,
that is, in capillary loop stage glomeruli [27]. Unlike the normal
adult glomerulus, BM-CSPG is transiently present in the lamina
rara interna of the GBM, a phase in renal development during
which the glomerular capillaries and mesangium are undergoing
substantial growth and reorganization.
A logical extension of those developmental studies was to
examine the possibility that the expression of BM-CSPG might
be altered in diabetic nephropathy, a disease where the glomer-
ular capillaries and mesangial matrix also undergo growth and
reorganization. Our initial light microscopy studies [46; McCar-
thy et al, submitted for publicationi of streptozocin-treated rats
with two months duration of untreated diabetes mellitus
showed BM-CSPG in the capillary ioops of some glomeruli. The
distribution of affected glomeruli appeared to be in random
clusters similar to that reported by Horlyck, Gunderson and
Osterby [47]. Subsequent immunoelectron microscopy studies
showed BM-CSPG present in affected capillaries in areas where
the GBM appeared to be thickened. BM-CSPG immediately
subtended the cell membranes of the capillary endothelial cells
(Fig. 2B), but because of the method by which BM-CSPG was
immunolocalized [27] we were unable to determine whether
BM-CSPG was present within the lamina rara interna (LRI) of
the GBM or lying in a space formed between the LRI and
capillary endothelial cell. In some areas of the affected capil-
laries, the focal accumulation of BM-CSPG within the suben-
dothelial space appeared to dislodge portions of the endothelial
cell body from the GBM proper. Within the mesangial matrix of
affected glomeruli there appeared to be an increase in the
relative density of BM-CSPG-associated peroxidase staining
when compared with that of control animals, suggesting an
increase in the amount of BM-CSPG present within the mesan-
gial matrices of diabetic animals. However, the pattern of
BM-CSPG deposition within the mesangial matrix of diabetic
animals remained identical to control animals, that is, the
proteoglycan immediately subtended the paramesangial GBM
that delineates a distinctive compartment within the me-
sangium.
Since the abnormal presence of BM-CSPG in the subendo-
thelial space of the capillary GBM is associated with histoar-
chitectural changes within the capillary wall, it becomes impor-
tant to determine which cellular population is stimulated to
abnormally produce BM-CSPG in the diabetic kidney. Results
from our developmental studies potentially exclude the visceral
epithelial cells (podocytes) from this process and suggest that
the capillary endothelial cells may synthesize BM-CSPG. Al-
ternatively, there is compelling evidence from other investiga-
tors suggesting that the source of subendothelial BM-CSPG
may be the diabetic mesangium. It is possible that the expand-
ing mesangium extends into the potential space formed between
the capillary cell body and the GBM. Recent scanning electron
microscopy have shown that the subendothelial material
present in the capillaries is continuous with the material com-
prising the mesangial matrix [48]. If so, the fact that BM-CSPG
is normally confined to the mesangial matrix makes it a unique
marker to track the progression of disease.
Matrix turnover in the glomerulus
Enhanced accumulation of extracellular matrix may in part
result from decreased turnover. There have been relatively few
studies of glomerular basement membrane (GBM) and mesan-
gial matrix turnover in vivo. A slow turnover rate has been
demonstrated for the collagenous components of the GBM,
similar to that of the fibrillar collagens (t¼> 100hr) and slower
than that of other glomerular proteins [49]. The low catabolic
rate of this major component may partially explain the thicken-
ing of the glomerular basement membrane in disease states such
as diabetes.
In vivo studies have indicated a more rapid turnover for
glycosaminoglycans of the GBM and renal cortex than that of
collagen and other macromolecules [50, 51]. Both studies
indicated a similar turnover rate overall, but demonstrated
different kinetics. Barry and Bowness showed a two phase
pattern for glycosaminoglycan turnover from the whole rat
kidney cortex [50]. The first phase from 24 to 120 hours had a t'/2
of two days and the second from 120 to 336 hours with t½ of five
to six days. A tV2 of seven days was found for the turnover of
35S-macromolecules in GBM extracted from rat glomeruli [51].
Exact comparisons cannot be made because of differences in
labeling techniques and tissue examined.
Subsequently, Beavan et a! [52] used an in vivo pulse chase
protocol with a short labeling period (7 hr) to include turnover
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Fig. 2. Ultrastructural immunolocalization of
BM-CSPG in glomeruli from normal (A) and
streptozocin-induced diabetic (B) rats. BM-
CSPG was immunolocalized using an in vivo
immunolabeling technique with monoclonal
antibodies against BM-CSPG conjugated with
horseradish peroxidase as previously
described [27]. BM-CSPG associated
immunoreactivity is indicated in the
photomicrographs by the black, electron-
dense reaction product within the tissue
section. In normal glomeruli (A) BM-CSPG
immunoreactivity is confined exclusively to
the mesangial matrix (M) immediately
subtending the paramesangial GBM
(arrowheads) and entirely lacking in the
peripheral capillary GBM (delimited by
arrows). In diabetic glomeruli BM-CSPG is
also present in the mesangial matrix (M) with
a pattern of distribution similar to that of
normal animals, that is, BM-CSPG continues
to subtend the paramesangial GBM
(arrowheads). However, BM-CSPG
immunoreactivity is also found within the
peripheral capillary, immunolocalized to an
area directly beneath the capillary
endothelium (arrows), possibly associated
with the lamina rara interna of the GBM. In
this section the BM-CSPG immunoreactive
material within the capillary (arrows) appears
to be continuous with that of the mesangial
matrix (M). Abbreviations are: P, podocyte;
E, endothelial cell. Bar = 2.5 m (photograph
courtesy of D.J. McCarthy).
occurring within the first 24 hours after labeling. Additionally chloride. Autoradiographic evidence indicated a complex bi-
the proteoglycans were fixed in the kidneys, immediately prior phasic turnover pattern. Biochemical analysis revealed total
to glomerular isolation, by perfusion with cetyl pyridinium heparan sulfate proteoglycans (HSPG) to have t¼ of 20 hours
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